✦ LIBER ✦

Promising results from Henkel in 1Q 2007

Book ID: 114376120
Publisher: Elsevier Science
Year: 2007
Weight: 53 KB
Volume: 2007
Category: Article
ISSN: 1351-4210
DOI: 10.1016/s1351-4210(07)70247-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Favourable results for Henkel in 1Q 2002

📂 Article 📅 2002 🏛 Elsevier Science ⚖ 39 KB

The increase in the net loss primarily reflects clinical trial costs incurred for the company's lead product, Surfaxin, currently in three Phase III trials and one Phase II trial. Selected updates on the company's progress in 1Q 2002 are included in the report. Revenues from collaborative agreements

Clorox 1Q 2007 results

📂 Article 📅 2007 🏛 Elsevier Science ⚖ 49 KB

Jotun results 1Q 2007

📂 Article 📅 2007 🏛 Elsevier Science ⚖ 424 KB

Surge in results for Henkel in Jan-Sep 2

Surge in results for Henkel in Jan-Sep 2007

📂 Article 📅 2008 🏛 Elsevier Science ⚖ 54 KB

Albemarle reports 1Q 2007 results

📂 Article 📅 2007 🏛 Elsevier Science ⚖ 53 KB

Novozymes results 1-3Q 2007

📂 Article 📅 2007 🏛 Elsevier Science ⚖ 48 KB

Acquired by Carlyle in Jun 2007, PQ Corp is to merge with Ineos Silicas, thereby creating a new giant in the silica compounds sector. The new entity (which will retain the PQ Corporation name) will be a 60:40 joint venture between Carlyle and Ineos. In 2005 the UK group put the business up for sale